IGC Pharma Inc (IGC)
| Market Cap | 28.61M |
| Revenue (ttm) | 1.22M |
| Net Income (ttm) | -14.15M |
| Shares Out | 66.54M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 229,715 |
| Open | 0.438 |
| Previous Close | 0.439 |
| Day's Range | 0.417 - 0.448 |
| 52-Week Range | 0.250 - 0.910 |
| Beta | 1.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 14, 2024 |
About IGC
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experienci... [Read more]
Financial Performance
In 2022, IGC Pharma's revenue was $911,000, an increase of 129.47% compared to the previous year's $397,000. Losses were -$11.51 million, -23.38% less than in 2021.
Financial StatementsNews
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two.
IGC Pharma Adds Advisor in Artificial Intelligence
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Adds Advisor in Artificial Intelligence.
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock.
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation.
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024.
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline.
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.
IGC Pharma Reports Third Quarter Fiscal 2024 Results
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for...
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.
IGC Pharma Reports Second Quarter Fiscal 2024 Results
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer's Association International Conference.
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research.
IGC Pharma Announces a $3 Million Private Placement of its Common Stock
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Announces a $3 Million investment: strengthen IGC's working capital & support the advancement of our IGC-AD1 Phase-2 clinical trial.
IGC Pharma Receives Notice of Allowance for Patent on Seizures
POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC received Notice of Allowance from Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures.
IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award
POTOMAC, Maryland--(BUSINESS WIRE)-- #IGC--Professor T. Govindaraju, IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award .
IGC Pharma to Present at LD Micro Invitational XIII
Presentation on Tuesday, June 6 at 3:00 PM PT Los Angeles, California--(Newsfile Corp. - May 18, 2023) - IGC Pharma, Inc. (NYSE American: IGC) announced today that it will be presenting at the 13th An...